NUDT12: A Potential Drug Target and Biomarker (G83594)

Target Name: NUDT12

NCBI ID: G83594

NUDT12

NUDT12: A Potential Drug Target and Biomarker

Nucleoside diphosphate linked moiety X-type motif 12 (NUDT12) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. NUDT12 is a key regulator of gene expression and has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation.

The NUDT12 molecule is composed of a core RNA structure that is flanked by a series of phosphate groups on the 5' and 3' ends. The 3' end of the NUDT12 molecule contains a unique motif that is composed of a specific sequence of base pairs, which is similar to that of DNA. This motif has been named the \"X-type motif\" and is thought to play a structural role in the regulation of gene expression.

Several studies have identified the NUDT12 molecule as a potential drug target because of its ability to interact with and inhibit the activity of specific proteins. For example, research has shown that NUDT12 can inhibit the activity of the protein kinase A-TOR, which is known to play a role in cell growth and survival. Additionally, NUDT12 has been shown to interact with the protein FAK, which is involved in cell adhesion and migration.

In addition to its potential as a drug target, NUDT12 has also been identified as a potential biomarker for a variety of diseases. For example, research has shown that NUDT12 levels are elevated in the brains of individuals with Alzheimer's disease, which is thought to be caused by the accumulation of neurode waste. Additionally, NUDT12 has been shown to be elevated in the blood samples of individuals with cancer, which may be a potential indicator of the disease.

The NUDT12 molecule has also been shown to play a role in the regulation of cellular processes that are important for human health, such as cell apoptosis. Apoptosis is a natural process that helps the body eliminate damaged or dysfunctional cells. However, in diseases such as cancer, apoptosis may be disrupted, leading to the development of cancer cells. Research has shown that NUDT12 can inhibit the activity of enzymes that are involved in apoptosis, which may be a potential strategy for targeting cancer cells.

In conclusion, NUDT12 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. NUDT12's unique motif and its ability to interact with specific proteins make it an attractive target for drug development. Additionally, NUDT12's role in regulating cellular processes that are important for human health, such as apoptosis, makes it a potential biomarker for a variety of diseases. Further research is needed to fully understand the potential of NUDT12 as a drug target and biomarker.

Protein Name: Nudix Hydrolase 12

Functions: mRNA decapping enzyme that specifically removes the nicotinamide adenine dinucleotide (NAD) cap from a subset of mRNAs by hydrolyzing the diphosphate linkage to produce nicotinamide mononucleotide (NMN) and 5' monophosphate mRNA (PubMed:31101919, PubMed:31875550). The NAD-cap is present at the 5'-end of some RNAs; in contrast to the canonical N7 methylguanosine (m7G) cap, the NAD cap promotes mRNA decay (PubMed:31101919). Preferentially acts on NAD-capped transcripts in response to nutrient stress (PubMed:31101919). Also acts on free nicotinamide adenine dinucleotide molecules: hydrolyzes NAD(H) into NMN(H) and AMP, and NADPH into NMNH and 2',5'-ADP (PubMed:12790796). May act to regulate the concentration of peroxisomal nicotinamide nucleotide cofactors required for oxidative metabolism in this organelle (PubMed:12790796). Regulates the levels of circadian clock components PER1, PER2, PER3 and CRY2 in the liver (By similarity)

The "NUDT12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUDT12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets